These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

809 related articles for article (PubMed ID: 34374967)

  • 1. Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020.
    Rocca E; Gauffin O; Savage R; Vidlin SH; Grundmark B
    Drug Saf; 2021 Sep; 44(9):987-998. PubMed ID: 34374967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database.
    Gérard AO; Laurain A; Fresse A; Parassol N; Muzzone M; Rocher F; Esnault VLM; Drici MD
    Clin Pharmacol Ther; 2021 Apr; 109(4):1021-1024. PubMed ID: 33340409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
    Zekarias A; Watson S; Vidlin SH; Grundmark B
    Drug Saf; 2020 Dec; 43(12):1309-1314. PubMed ID: 32978702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications.
    Charan J; Kaur RJ; Bhardwaj P; Haque M; Sharma P; Misra S; Godman B
    Expert Rev Clin Pharmacol; 2021 Jan; 14(1):95-103. PubMed ID: 33252992
    [No Abstract]   [Full Text] [Related]  

  • 5. Neuropsychological adverse drug reactions of Remdesivir: analysis using VigiBase, the WHO global database of individual case safety reports.
    Lee S; Yang JW; Jung SY; Kim MS; Yon DK; Lee SW; Kang HC; Dragioti E; Tizaoui K; Jacob L; Koyanagi A; Salem JE; Kostev K; Lascu A; Shin JI; Kim JH; Smith L
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7390-7397. PubMed ID: 34919240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study.
    Garcia P; Revet A; Yrondi A; Rousseau V; Degboe Y; Montastruc F
    Drug Saf; 2020 Dec; 43(12):1315-1322. PubMed ID: 33078372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: a preliminary report.
    Falcão F; Viegas E; Carmo I; Soares J; Falcao M; Solano M; Cavaco P; Mendes D; Rijo J; Povoa P; Pais Martins A; Carmo E; Mansinho K; Fonseca C; Campos L; Carvalho A; Mirco A; Farinha H; Aldir I; Correia J
    Eur J Hosp Pharm; 2021 Sep; 28(5):248-253. PubMed ID: 33452110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database.
    Jung SY; Kim MS; Li H; Lee KH; Koyanagi A; Solmi M; Kronbichler A; Dragioti E; Tizaoui K; Cargnin S; Terrazzino S; Hong SH; Abou Ghayda R; Kim NK; Chung SK; Jacob L; Salem JE; Yon DK; Lee SW; Kostev K; Kim AY; Jung JW; Choi JY; Shin JS; Park SJ; Choi SW; Ban K; Moon SH; Go YY; Shin JI; Smith L
    Clin Transl Sci; 2022 Feb; 15(2):501-513. PubMed ID: 34719115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data.
    Singh A; Kamath A
    Expert Opin Drug Saf; 2021 Dec; 20(12):1559-1564. PubMed ID: 34328807
    [No Abstract]   [Full Text] [Related]  

  • 10. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhang D; Du G; Du R; Zhao J; Jin Y; Fu S; Gao L; Cheng Z; Lu Q; Hu Y; Luo G; Wang K; Lu Y; Li H; Wang S; Ruan S; Yang C; Mei C; Wang Y; Ding D; Wu F; Tang X; Ye X; Ye Y; Liu B; Yang J; Yin W; Wang A; Fan G; Zhou F; Liu Z; Gu X; Xu J; Shang L; Zhang Y; Cao L; Guo T; Wan Y; Qin H; Jiang Y; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Lancet; 2020 May; 395(10236):1569-1578. PubMed ID: 32423584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis.
    Rezagholizadeh A; Khiali S; Sarbakhsh P; Entezari-Maleki T
    Eur J Pharmacol; 2021 Apr; 897():173926. PubMed ID: 33549577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
    Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G
    BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compassionate Use of Remdesivir in Children With Severe COVID-19.
    Goldman DL; Aldrich ML; Hagmann SHF; Bamford A; Camacho-Gonzalez A; Lapadula G; Lee P; Bonfanti P; Carter CC; Zhao Y; Telep L; Pikora C; Naik S; Marshall N; Katsarolis I; Das M; DeZure A; Desai P; Cao H; Chokkalingam AP; Osinusi A; Brainard DM; Méndez-Echevarría A
    Pediatrics; 2021 May; 147(5):. PubMed ID: 33883243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remdesivir as a broad-spectrum antiviral drug against COVID-19.
    Hong YN; Xu J; Sasa GBK; Zhou KX; Ding XF
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):541-548. PubMed ID: 33506946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1).
    Qaseem A; Yost J; Etxeandia-Ikobaltzeta I; Abraham GM; Jokela JA; Forciea MA; Miller MC; Humphrey LL; ; Centor RM; Andrews R; Haeme R; Kansagara DL; Marcucci M
    Ann Intern Med; 2021 Feb; 174(2):229-236. PubMed ID: 33017175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019.
    Montastruc F; Thuriot S; Durrieu G
    Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2835-2836. PubMed ID: 32721580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of remdesivir in the treatment of acute SARS-CoV-2 infection in pediatric patients.
    Player B; Huppler AR; Pan AY; Liegl M; Havens PL; Ray K; Mitchell M; Graff K
    BMC Infect Dis; 2024 Sep; 24(1):987. PubMed ID: 39289614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral treatment for COVID-19: the evidence supporting remdesivir.
    Richardson C; Bhagani S; Pollara G
    Clin Med (Lond); 2020 Nov; 20(6):e215-e217. PubMed ID: 32863273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatobiliary Adverse Drug Reactions Associated With Remdesivir: The WHO International Pharmacovigilance Study.
    Kim MS; Jung SY; Lee SW; Li H; Koyanagi A; Kronbichler A; Dragioti E; Tizaoui K; Wasuwanich P; Hong SH; Ghayda RA; Yoo HW; Kim H; Jacob L; Salem JE; Kostev K; Shin YH; Kim SY; Gamerith G; Yon DK; Shin JI; Smith L
    Clin Gastroenterol Hepatol; 2021 Sep; 19(9):1970-1972.e3. PubMed ID: 33940227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remdesivir for patients with COVID-19.
    Wu PE; Morris AM
    CMAJ; 2021 Jan; 193(4):E125. PubMed ID: 33408097
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 41.